ValuEngine Lowers Kamada (KMDA) to Sell
ValuEngine cut shares of Kamada (NASDAQ:KMDA) from a hold rating to a sell rating in a report released on Thursday.
A number of other analysts also recently weighed in on the company. TheStreet upgraded Kamada from a c rating to a b rating in a report on Friday, February 9th. Zacks Investment Research upgraded Kamada from a sell rating to a hold rating in a report on Friday, February 9th. HC Wainwright restated a buy rating on shares of Kamada in a report on Thursday, February 8th. Finally, Chardan Capital assumed coverage on Kamada in a report on Friday, February 2nd. They issued a buy rating and a $7.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Kamada currently has an average rating of Hold and an average price target of $7.00.
Kamada (NASDAQ KMDA) traded up $0.05 during midday trading on Thursday, reaching $5.25. The company had a trading volume of 18,619 shares, compared to its average volume of 17,034. The firm has a market capitalization of $211.38, a P/E ratio of 30.88 and a beta of 1.12. Kamada has a 1-year low of $3.75 and a 1-year high of $8.61. The company has a quick ratio of 2.58, a current ratio of 3.30 and a debt-to-equity ratio of 0.02.
A number of institutional investors and hedge funds have recently modified their holdings of KMDA. Jane Street Group LLC bought a new stake in Kamada during the third quarter valued at $112,000. Worth Venture Partners LLC bought a new stake in Kamada during the third quarter valued at $246,000. ARK Investment Management LLC bought a new stake in Kamada during the fourth quarter valued at $251,000. Analyst IMS Investment Management Services Ltd. boosted its position in Kamada by 125.5% during the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Kamada by 6.5% during the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after acquiring an additional 28,382 shares during the last quarter. 6.31% of the stock is currently owned by institutional investors and hedge funds.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.